Article

A Concise Synthesis of a beta-Lactamase Inhibitor

Department of Process Research, Merck and Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, USA.
Organic Letters (Impact Factor: 6.32). 09/2011; 13(20):5480-3. DOI: 10.1021/ol202195n
Source: PubMed

ABSTRACT MK-7655 (1) is a β-lactamase inhibitor in clinical trials as a combination therapy for the treatment of bacterial infection resistant to β-lactam antibiotics. Its unusual structural challenges have inspired a rapid synthesis featuring an iridium-catalyzed N-H insertion and a series of late stage transformations designed around the reactivity of the labile bicyclo[3.2.1]urea at the core of the target.

0 Followers
 · 
195 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The emergence of multi-drug-resistant bacteria and the lack of new antibiotics in the antibiotic drug development pipeline, especially those with new modes of action, is a major health concern. This review lists the 20 new antibiotics launched since 2000 and records the 40 compounds currently in active clinical development. Compounds in the pipeline from new antibiotic classes are reviewed in detail with reference to their development status, mode of action, spectrum of activity and lead discovery. In addition, the NP or synthetic derivation is discussed, with activity against Gram-negative bacteria highlighted.
    The Journal of Antibiotics 06/2011; 64(6):413-25. DOI:10.1038/ja.2011.44 · 2.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: beta-Lactam antibiotics are one of the most important antibiotic classes but are plagued by problems of resistance and the development of new beta-lactam antibiotics through side chain modification of existing beta-lactam classes is not keeping pace with resistance development. In this perspective we summarize small molecule strategies to overcome resistance to beta-lactam antibiotics. These approaches include the development of beta-lactamase inhibitors and compounds that interfere with the ability of the bacteria to sense an antibiotic threat and activate their resistance mechanisms.
    The Journal of Organic Chemistry 03/2013; 78(9). DOI:10.1021/jo400236f · 4.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recently, a small number of diverse iridium complexes have been shown to catalyze unusual atom transfer C–H functionalization reactions. To further our understanding and enhance the utility of iridium complexes for C–H functionalization, we report the design and synthesis of a family of iridium(III)-bis(oxazolinyl)phenyl complexes. The ability to tune the ligand environment around the metal in these systems is exploited to design complexes with the ability to catalyze the asymmetric insertion of donor/acceptor iridium carbenoids into activated C–H bonds. Low catalyst loadings (0.5 mol%) routinely lead to excellent reaction yields (51–99%) and enantioselectivities (83–99%). Density functional theory calculations provide compelling evidence that in these complexes the carbene binds to the iridium cis to the phenyl group of the bis(oxazolinyl)phenyl ligand. This finding is vital for understanding the observed stereochemical induction and is of particular significance in the field of enantioselective transition metal-catalysed atom transfer reactions utilizing oxazoline–X–oxazoline tridentate ligands, as previously employed stereochemical models for these ligand sets are based on the assumption that reactive ligands and Lewis bases bind trans to the central X ligand.
    Chemical Science 04/2013; 4(6):2590-2596. DOI:10.1039/C3SC50886B · 8.60 Impact Factor